Serum Trimethylamine-N-Oxide and Its Precursors as a Diagnostic Biomarker Panel for Non-Muscle-Invasive Bladder Cancer
≤ 0.0001). A composite risk score integrating all four metabolites demonstrated excellent discriminatory capacity (AUC = 0.958, 95% CI 0.926-0.991). The TMAO metabolic axis can be used as a minimally invasive biomarker panel for NMIBC. Further large, prospective, multicenter studies integrating metabolomic and microbiome profiling are needed to validate the findings.
Authors
- Yeşim Sağlıcan (ORCID: https://orcid.org/0000-0002-7666-9021)
- Ömer Burak Argun (ORCID: https://orcid.org/0000-0003-0127-0005)
- Aysel Özpınar (ORCID: https://orcid.org/0000-0002-7399-4929)
- Muhittin A. Serdar (ORCID: https://orcid.org/0000-0002-3014-748X)
- Ümit İnce (ORCID: https://orcid.org/0000-0002-6113-661X)
- Ali Rıza Kural (ORCID: https://orcid.org/0000-0003-3488-0571)
- Osman Acar
- Ceyda Sonmez
- Aleyna Baltacioglu
- Asıf Yıldırım
Institutions
- Istanbul Kent University (TR)
- Kent Hastanesi (TR)
- Acıbadem Adana Hospital (TR)
- Istanbul Medeniyet University (TR)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2026-04-17
- DOI
- https://doi.org/10.3390/ijms27083591
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00